Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Bulgaria before the introduction of pneumococcal conjugate vaccine

References

• World Health Organization. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104.
   PubMedGoogle Scholar
• Clarke SC. Control of pneumococcal disease in the United Kingdom — the start of a new era. J Med Microbil. 2006;55:975–80.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998–2008. MMWR Morb Mortal Wkly Rep. 2008;57(6):144–8.
   PubMedGoogle Scholar
• O’Brien KL, Dagan R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine. 2003;21(17–18):1815–25.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Summary of positive opinion for Prevenar 13 [Internet]. London: EMEA; 24 Sep 2009. Available from: http//www.emea.europa.eu/ (Accessed 24 September 2009).
   Google Scholar
• World Health Organization. Streptococcus pneumoniae (Pneumococcus) [Internet]. [cited 2010 Apr] Available from: http://www.who.int/immunization_delivery/new_vaccines/pneumo.
   Google Scholar
• Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197–209.
   PubMed Web of Science ®Google Scholar
• Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8:785–95.
   PubMed Web of Science ®Google Scholar
• Imöhl M, Reinert RR, Mutscher C, van der Linden M. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol. 2010;10:299.
   PubMedGoogle Scholar
• Sorensen UBS. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol. 1993;31:2097–100.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2010. M100–S20.
   Google Scholar
• Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother. 1996;40:2562–66.
   PubMed Web of Science ®Google Scholar
• Montanari MP, Mingoia M, Giovanetti E, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol. 2003;41:428–31.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al.. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–46.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Gurler N, Yaman A, Ozturk C, Oksuz L, Ozkan S, et al.. Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide. Clin Vaccine Immunol. 2011;18(6);1028–30.
   PubMed Web of Science ®Google Scholar
• Zissis NP, Syriopoulou V, Kafetzis D, Daikos GL, Tsilimingaki A, Galanakis E, et al.. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur J Pediatr. 2004;163(7):364–8.
   PubMed Web of Science ®Google Scholar
• Dobay O, Ungvari A, Kardos S, Kristof K, Hajdu E, Szabo J, et al.. Genotypic and phenotypic characterisation of invasive Streptococcus pneumoniae isolates from Hungary, and coverage of the conjugate vaccines. J Clin Pathol. 2010;63(12):1116–20.
   PubMed Web of Science ®Google Scholar
• Skoczynska A, Sadowy E, Bojarska K, Strzelecki J, Kuch A, Golebiewska A, et al.. The current status of invasive pneumococcal disease in Poland. Vaccine. 2011;29(11):2199–205.
   PubMed Web of Science ®Google Scholar
• Setchanova L, Tomasz A. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates from Bulgaria. J Clin Microbiol. 1999;37:638–48.
   PubMed Web of Science ®Google Scholar
• Fenoll A, Granizo JJ, Aguilar L, Gimenez MJ, Aragoneses-Fenoll L, Hanquet G, et al.. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009;47(4):1012–20.
   PubMed Web of Science ®Google Scholar
• Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al.. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196(9):1346–54.
   PubMed Web of Science ®Google Scholar
• Prymula R, Hanovcova I, Splino M, Kriz P, Motlova J, Lebedova V, et al.. Impact of the 10-valent pneumococcal non-typable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011;29(10):1959–67.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613–20.
   PubMed Web of Science ®Google Scholar
• Setchanova L, Ouzounova-Raykova V, Zhelezova G, Mitov I. Prevalence and macrolide resistance phenotypes and genotypes among clinical isolates of Streptococcus pneumoniae collected in Sofia, Bulgaria from 2001 to 2005. J Chemother. 2007;19:256–62.
   PubMed Web of Science ®Google Scholar
• Setchanova L. Clinical isolates and nasopharyngeal carriage of antibiotic-resistant Streptococcus pneumoniae in hospital for infectious diseases, Sofia, Bulgaria, 1991–1993. Microbial Drug Resist. 1995;1:79–84.
   PubMed Web of Science ®Google Scholar